报告题目：Diverse Applications for Bacterial-based Engineering
报告人：Blaine Pfeifer
报告人单位：State University of New York, Buffalo, USA
报告时间：2017年7月20号10:50 — 11：50
报告地点：微生物所E301会议室
主持人：娄春波 研究员
报告摘要：This presentation will feature the use of Escherichia coli to support research goals that span natural product biosynthesis and vaccine design. Each application is driven by the metabolic and process engineering afforded by the E. coli vehicle. Figure 1 depicts the research applications that will be discussed. Specifically, as a heterologous host for complex natural product biosynthesis, E. coli has been the production route to erythromycin (anantibiotic) and yersiniabactin (a siderophore). The production platform for erythromycin has been engineered for molecular diversity with the associated goal of generating variation in final bioactivity. Similarly, E. coli has been engineered to produce yersiniabactin, a natural product with a propensity for iron sequestration. Using this platform, the product has been re-purposed for metal removal and recovery from aqueous streams. A final application features E. coli as an engineering-ready antigen delivery vehicle in the context of vaccine design. Here, metabolic engineering is applied to direct and enhance the resulting immune response, and strong protection data has been collected from animal immunization-challenge assays using pneumococcal disease as an initial indication.
报告人简介：
Pfeifer 教授一直从事微生物代谢工程研究。首次实现了天然抗生素红霉素分子以及抗肿瘤植物药紫杉醇的异源生物合成；成功将紫杉醇关键前体物taxadiene的产量提高到1克每升，相关成果分别于2001年和2010年在Science 正刊发表，受到国际学术界广泛关注，奠定了聚酮类以及二萜类药物异源生物合成新领域的研究基础。近五年来致力于天然产物活性分子的异源生物合成以及药物控制释放研究，开发了新型大肠杆菌-阳离子聚合物复合材料，以及铁呋啉-磷脂双分子纳米胶囊，在智能疫苗设计和药物靶向运输领域具有巨大的应用潜力。
欢迎科研人员和研究生朋友踊跃参加！
